BioNTech SE (WBO:BNTX) Total Assets : €22,257 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Total Assets?

BioNTech SE's Total Assets for the quarter that ended in Mar. 2024 was €22,257 Mil.

During the past 12 months, BioNTech SE's average Total Assets Growth Rate was -30.10% per year. During the past 3 years, the average Total Assets Growth Rate was 81.30% per year. During the past 5 years, the average Total Assets Growth Rate was 130.20% per year.

During the past 8 years, BioNTech SE's highest 3-Year average Total Assets Growth Rate was 284.10%. The lowest was 51.00%. And the median was 81.30%.

Total Assets is connected with ROA %. BioNTech SE's annualized ROA % for the quarter that ended in Mar. 2024 was -5.57%. Total Assets is also linked to Revenue through Asset Turnover. BioNTech SE's Asset Turnover for the quarter that ended in Mar. 2024 was 0.01.

BioNTech SE Total Assets Historical Data

The historical data trend for BioNTech SE's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Total Assets Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

797.65

2,318.60

15,830.80

23,279.10

23,006.30

BioNTech SE Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															22,079.00	22,225.60	22,207.20	23,006.30	22,256.80

BioNTech SE Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

BioNTech SE's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	20245.9	+	2760.4
	=	23,006

BioNTech SE's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	19968.2	+	2288.6
	=	22,257

BioNTech SE (WBO:BNTX) Total Assets Explanation

Total Assets is connected with ROA %.

BioNTech SE's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-1260.4	/	( (23006.3	+	22256.8)	/ 2 )
	=	-1260.4	/	22631.55
	=	-5.57 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

BioNTech SE's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	187.6	/	( (23006.3	+	22256.8)	/ 2 )
=	187.6	/	22631.55
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

BioNTech SE Total Assets Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (WBO:BNTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (WBO:BNTX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.